Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: LeMaitre Vascular develops, manufactures, and markets medical devices and implants for vascular surgery. The company operates in a single segment with principal product lines including thoracic and abdominal stent grafts, anastomotic clips, and vascular grafts. Operations are headquartered in Burlington, Massachusetts, with international offices in Germany, Italy, and Japan.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2007 |
|---|---|---|---|
| Net Sales | $12,023 | $36,609 | $30,342 |
| Gross Profit | $8,103 | $25,478 | $22,564 |
| Gross Margin | 67.4% | 69.6% | 74.4% |
| Operating Income (Loss) | $170 | $(3,285) | $(2,966) |
| Net Loss | $(136) | $(3,626) | $(1,756) |
| Cash and Cash Equivalents | $13,163 | $13,163 | $7,752 |
| Marketable Securities | $6,000 | $6,000 | $16,198 |
| Total Current Assets | $35,960 | $35,960 | $41,766 |
| Total Current Liabilities | $6,484 | $6,484 | $10,045 |
| Long-Term Debt | $40 | $40 | $42 |
Liquidity: As of September 30, 2008, the company held $19.2 million in combined cash, cash equivalents, and marketable securities. The company maintains a $10.0 million revolving line of credit with no outstanding balance as of the reporting date.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19% for the quarter and 21% for the nine-month period compared to the prior year. Growth was driven by the inclusion of the Biomateriali acquisition (Dec 2007), the EndoRE product suite (Sep 2007), favorable foreign currency fluctuations, and higher average selling prices.
- Margin Compression: Gross margin decreased from 74.4% to 69.6% for the nine-month period. This decline was attributed to the inclusion of lower-margin sales from the Biomateriali subsidiary, inventory write-offs of approximately $0.4 million due to product improvements, and the mix of international sales.
- Operating Expenses: Total operating expenses decreased 13% for the quarter but increased 13% for the nine-month period. The nine-month increase was driven by higher R&D spending (18% increase) and general administrative costs, partially offset by a significant reduction in restructuring charges ($1.1M in 2008 vs. $1.1M in 2007, but with a much larger one-time charge in Q3 2007).
- Impairment Charges: The company recorded $0.5 million in impairment charges for the nine months ended September 30, 2008, primarily related to the write-down of intangible assets for a discontinued customer relationship at the Biomateriali subsidiary. This compares to only $7,000 in the prior year period.
- Foreign Currency: The company recorded a foreign currency loss of $0.3 million for the quarter and $0.1 million for the nine months, contrasting with gains in the prior year periods due to a stronger U.S. dollar.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management intends to maintain operating profitability through the remainder of 2008 and into 2009 but noted that future profitability is not assured. The company expects to increase operating expenses in R&D and clinical/regulatory affairs.
- Capital Needs: While current cash and marketable securities are deemed sufficient for the next 12 months, the company may require additional capital for future acquisitions. Management highlighted that capital markets are volatile, and financing may not be available on favorable terms.
- Regulatory Risks:
- UniFit Study: The FDA issued a Warning Letter in June 2008 regarding deficiencies in the conduct of the pivotal clinical trial for the UniFit Abdominal Stent Graft. The company has submitted corrective actions, but future FDA inspections could interrupt the trial.
- TAArget Study: The FDA has not yet approved the feasibility study (ENTRUST) for the TAArget Thoracic Stent Graft due to identified deficiencies in the application.
- Acquisition Contingencies:
- Biomateriali Indemnity: The company has demanded approximately $1.1 million in damages from the sellers of Biomateriali regarding undisclosed customer relationship issues and has ceased certain post-closing payments pending resolution.
- Contingent Payments: Potential contingent payments related to the Biomateriali acquisition could total up to $2.1 million, dependent on future performance and exchange rates.
- Unusual Items: A $0.1 million investment impairment charge was recorded in September 2008 related to an asset-backed security. Additionally, restructuring charges included $0.7 million for contractual obligations related to the termination of an Italian distributor.
Investor Verification Checklist
- Regulatory Status: Verify the current status of the FDA's review of the corrective actions for the UniFit clinical trial and the resubmission of the TAArget feasibility study application.
- Acquisition Integration: Monitor the resolution of the $1.1 million indemnity claim against Biomateriali sellers and the impact of the Sorin Biomedica purchase volume reduction on future revenues.
- Liquidity and Capital Markets: Assess the company's ability to secure financing for future acquisitions given the volatility in credit markets and the potential dilution of equity financing.
- Margin Trends: Track whether gross margins stabilize as the impact of the lower-margin Biomateriali acquisition and inventory write-offs normalizes.
- Foreign Exchange Exposure: Evaluate the impact of continued fluctuations in the Euro/U.S. Dollar exchange rate, as approximately 45% of sales are denominated in foreign currencies.